PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 20, 2023Journal of Clinical Oncology177 citationsOpen Access

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

View Full Paper
SPSehhoon ParkSamsung Medical CenterTKTae Min KimSeoul National University HospitalJHJi‐Youn HanNational Cancer Centre Japan

Key Points

Key points are not available for this paper at this time.

Abstract

To our knowledge, this study is the first randomized phase III study to demonstrate the clinical benefit of anti-PD-L1 antibody in combination with bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated NSCLC who have progressed on relevant targeted therapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Park et al. (2023) studied this question.

synapsesocial.com/papers/69d937bcc7f0c3ae80a3c4e5https://doi.org/10.1200/jco.23.01891
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer2017 · 2,514 citations
  2. 2New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 30,012 citations
  3. 3Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer2016 · 82 citations
  4. 4LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 7222022 · 49 citations
  5. 5Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis2016 · 851 citations